View clinical trials related to Dermal Filler.
Filter by:The goal of this clinical trial is to evaluate the safety and efficacy of Formaderm (hyaluronic acid) dermal filler injection for soft tissue augmentation. The main questions it aims to answer are: - The differences of Wrinkle Severity Rating Scale (WSRS) after the injection. - The differences of Global Aesthetic Improvement Scale (GAIS) after the injection. - The subjective satisfaction of treatment. - Safety Indicators of which incidences on the day of the injection or after the injection. Participants will be self-controlled and randomized for same period - received both trial product and control product at the same time. - re-visited on week 2, 4, 12, 24, 36, and 52 after injection. Researchers will compare if the test product is non-inferiority to Q-Med Restylane.
The results showed that subjects tolerated the Sodium Hyaluronate Gel for Injection (FACILLE®) well, with no systemic AEs, SAEs, and unanticipated AEs and associated with high satisfaction and self-evaluated effectiveness. Nearly half of the subjects maintained correction for 12 months and were satisfied with the product 3 years after the first injection.
This study is to evaluate the safety and effectiveness for the correction of aging mid-face of treatment group compared with the active control group.
This study is to evaluate the safety and effectiveness for the correction of aging mid-face of treatment group compared with the negative control group.
The aim of this study is to evaluate the safety and effectiveness of pain relief of modified sodium hyaluronate gel for injection when used for the correction of moderate or severe nasolabial folds.
Purpose of this study is the demonstration of safety and efficacy of the dermal fillers HYAcorp Lips and HYAcorp Face for restoration of the facial volume and contour.
Purpose of this study is the demonstration of safety and efficacy of the dermal fillers HYAPROF® SOFT and HYAPROF® BALANCE for restoration of the facial volume and contour.
The purpose of this study is to determine whether or not Recombinant DNA-based hyaluronidase (RDNAH/Hylenex recombinant), is safe and effective for dissolving hyaluronic acid (HA) dermal fillers.